Market: Nasdaq Copenhagen
Symbol: GEN
ISIN: DK0010272202
Industry : Health Care

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.

GEN 20/07/2018
Currency DKK
Volume 129,720
Previous Close 1,136.50
Number of Shares (mil) 61.46
Change (%) 1.02
Market Cap (mil) 69,850.25
Consolidated Key Figures (DKK'000) 2014 2015 2016 2017
Revenue 850,385 1,133,041 1,816,122 2,365,436
Net result 301,296 763,513 1,187,075 1,103,551
Assets 2,866,681 3,902,548 5,238,236 6,602,942
Shareholders' equity 2,032,939 3,486,720 4,826,696 6,272,192
Basic net result per share (DKK) 5.35 13.05 19.83 18.14
Diluted net result per share (DKK) 5.26 12.56 19.22 17.77
Year-end share market price (DKK) 360.30 917.50 1,173.00 1,029.00
Price / book value 10.09 15.67 14.67 10.04
Shareholders' equity per share (DKK) 35.69 58.57 79.98 102.51
Equity ratio 71% 89% 92% 95%
Number of employees (FTE) at year-end 173 186 205 257